跳至主要内容
临床试验/NCT00309530
NCT00309530已完成3 期

A Prospectively Randomized Phase III Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Patients With Operated Colon Carcinoma Dukes C (Stage III; T1-4, N1-30, M0).

Austrian Breast & Colorectal Cancer Study Group32 个研究点 分布在 1 个国家目标入组 598 人开始时间: 1990年10月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
598
试验地点
32
主要终点
Recurrence-free survival

研究概览

简要总结

This clinical investigation examined the effectivity 5-fluorouracil, of adding levamisol or interferon to 5-fluorouracil, and of a 5-fluorouracil/levamisol/interferon triple combination, in terms of recurrence-free and overall survival in curatively operable colon carcinoma Stage III.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with histologically verified, curatively operated colon carcinoma Stage III (R0, T1-4, N1-3, M0)
  • Age: less than 80 years
  • WHO Performace Status > 2
  • Adequate bone marrow reserve
  • Informed consent

排除标准

  • Rectal cancer
  • R1, R2, carcinosis peritonei
  • Start of chemo- or chemo-immunotherapy > 42 days postop; other adjuvant radiotherapy, chemotherapy or immunotherapy
  • Serious concomitant disease, in particular chronically inflammatory large intestine, cardiopathic disease, malignant second carcinoma

结局指标

主要结局

Recurrence-free survival

Overall survival

次要结局

未报告次要终点

研究者

研究点 (32)

Loading locations...

相似试验